Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q26827399)
Watch
English
Immunogenicity of biotherapy used in psoriasis: the science behind the scenes
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
PubMed
title
Immunogenicity of biotherapy used in psoriasis: the science behind the scenes
(English)
1 reference
stated in
PubMed
author name string
Denis Jullien
series ordinal
1
1 reference
stated in
Crossref
Jörg C. Prinz
series ordinal
2
1 reference
stated in
Crossref
Frank O. Nestle
series ordinal
3
1 reference
stated in
Crossref
language of work or name
English
1 reference
stated in
PubMed
publication date
January 2015
1 reference
stated in
PubMed
published in
Journal of Investigative Dermatology
1 reference
stated in
PubMed
volume
135
1 reference
stated in
PubMed
issue
1
1 reference
stated in
PubMed
page(s)
31-8
1 reference
stated in
PubMed
cites work
Anti-infliximab antibody status and its relation to clinical response in psoriatic patients: A pilot study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Prevention and prediction of inhibitor risk
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Injection-site reaction to etanercept: role of skin test in the diagnosis of such reaction and successful desensitization
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Preclinical models used for immunogenicity prediction of therapeutic proteins
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumato
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Immune response to a recombinant human TNFR55-IgG1 fusion protein: auto-antibodies in rheumatoid arthritis (RA) and multiple sclerosis (MS) patients have neither neutralizing nor agonist activities
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Antibody humanization: a case of the 'Emperor's new clothes'?
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Methotrexate polyglutamation in relation to infliximab pharmacokinetics in rheumatoid arthritis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Immunogenicity of Anti-TNF-alpha agents in autoimmune diseases.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Methotrexate reduces antibody responses to recombinant human alpha-galactosidase A therapy in a mouse model of Fabry disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Successful etanercept desensitization in a patient with severe injection site reactions
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pegylation: a novel process for modifying pharmacokinetics
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Differential effect of drug interference in immunogenicity assays
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Allergy to monoclonal antibodies: cutting-edge desensitization methods for cutting-edge therapies
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Anti-drug antibodies in psoriasis: a critical evaluation of clinical significance and impact on treatment response
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Antidrug antibodies in psoriasis: a systematic review
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Transient low-dose methotrexate induces tolerance to murine anti-thymocyte globulin and together they promote long-term allograft survival
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
[Anti-drug antibodies, auto-antibodies and biotherapy in psoriasis]
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Duration of remission of psoriasis therapies
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Immunogenicity of biological therapeutics: from assay to patient
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Dose-creep of Infliximab during psoriasis treatment: an observational study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Extent and consequences of antibody formation against adalimumab in patients with psoriasis: one-year follow-up
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Lack of Anti-drug Antibodies in Patients with Psoriasis Well-controlled on Long-term Treatment with Tumour Necrosis Factor Inhibitors
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
New FDA draft guidance on immunogenicity
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Antinuclear antibodies associate with loss of response to antitumour necrosis factor-alpha therapy in psoriasis: a retrospective, observational study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Drug interference in immunogenicity assays depends on valency
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Immunogenicity of therapeutic proteins: clinical implications and future prospects
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The immunogenicity of polyethylene glycol: facts and fiction
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Inhibitors - cellular aspects and novel approaches for tolerance
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Anti-TNF therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A novel method for the detection of antibodies to adalimumab in the presence of drug reveals “hidden” immunogenicity in rheumatoid arthritis patients
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
IgG4 Production Against Adalimumab During Long Term Treatment of RA Patients
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Dealing with immunogenicity of biologicals: assessment and clinical relevance
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Evaluation of pre-existing antibody presence as a risk factor for posttreatment anti-drug antibody induction: analysis of human clinical study data for multiple biotherapeutics
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pharmacogenetics and the immunogenicity of protein therapeutics
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FJID.2014.295
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1038/JID.2014.295
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
2298213
Dimensions Publication ID
1003404878
0 references
OpenCitations bibliographic resource ID
2298213
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
2298213
PubMed publication ID
25120005
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
2298213
ResearchGate publication ID
264798176
0 references
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
